Bungarus multicinctus and Bungarus candidus venom neurotoxic and enzymatic protein fractions

This target refers to the high-molecular-weight protein fractions isolated from the venom of Bungarus multicinctus (Many-banded krait) and Bungarus candidus (Malayan krait). These fractions are primarily composed of potent presynaptic neurotoxins known as beta-bungarotoxins and various enzymes including phospholipase A2 (PLA2), acetylcholinesterase, and L-amino acid oxidase [1, 2]. Beta-bungarotoxins function by exerting PLA2 activity at the presynaptic nerve terminal, leading to an initial surge of neurotransmitter release followed by the complete and often irreversible exhaustion of synaptic vesicles, resulting in flaccid paralysis [1]. The enzymatic components such as PLA2 and acetylcholinesterase further exacerbate systemic toxicity by disrupting cell membranes and interfering with cholinergic signaling [2]. In clinical practice, these protein fractions are the primary targets for monovalent or polyvalent antivenoms, which utilize purified antibodies to sequester and neutralize the toxins in the bloodstream [3]. Recent research also highlights these fractions as targets for small-molecule inhibitors like varespladib, which specifically aims to block the enzymatic PLA2 activity that drives much of the venom's lethality [4]. This target is classified as 'incorrect' in a strictly proteomic sense because it represents a complex mixture of multiple distinct proteins rather than a single molecular entity.

Other names

Krait venom neurotoxinsBeta-bungarotoxinsBungarus multicinctus venom proteinsBungarus candidus venom proteinsVenom phospholipase A2 (PLA2)Krait venom enzymatic fractions

Therapeutic intervention involves the neutralization of toxic epitopes by specific antibodies (antivenom) to prevent binding to physiological targets, or the competitive inhibition of enzymatic sites, such as the inhibition of phospholipase A2 activity by small molecules like varespladib [4].